Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-10-20-Speech-3-794"

PredicateValue (sorted: default)
rdf:type
dcterms:Date
dcterms:Is Part Of
dcterms:Language
lpv:document identification number
"en.20101020.30.3-794"2
lpv:hasSubsequent
lpv:speaker
lpv:spoken text
"Mr President, I think we should start off by welcoming some of these statements that were made this evening and the fact that, following the Tokyo Round, the Commission released the text to the Parliament, which will ultimately be in a position to give consent or not to these agreements. I think the move towards transparency is something which should be welcomed across the Parliament. After all, that was one of the areas of consensus across the Parliament – we may have disagreed on certain elements, but we agreed on more and more transparency. An increase in transparency means that we reduce false speculation about the content of the negotiations, but also, to be fair, highlights the positive role played by the Commission in trying to persuade the negotiating partners of the need for greater transparency. I think we played a role in this Parliament in putting pressure on the Commission, so it, in turn, can talk to its negotiating partners about the need for greater transparency. There are obviously differences of opinion in this House on intellectual property rights. It is clearly a key issue for copyright and trademark holders. ACTA, I hope, is an important step in terms of enforcement among all active parties and builds on the TRIPS agreement of the mid-1990s. Personally, I think a distinction should be made between the digital world and the world of atoms; in a world of increased processing power, increased storage and increased bandwidth, you see a tendency towards a price of zero and many in the music industry, for example, have failed to react. I understand from speaking to legal experts, however, that it is very difficult to codify that in an agreement. When it comes to the production of generic medicines, I am glad that ACTA protects copyrights and trademarks while excluding patents from border measures, so you avoid the seizure of generic medicine in transit through the EU. But I do have a question since the Commission was not responsible for negotiating on behalf of the EU when it came to the criminal enforcement chapter which was dealt with by the Council on behalf of Member States. How, when we have this debate about concerns over the criminal sanctions, do we intend to reconcile the two different negotiations between the civil and the criminal chapter? It is a question for you, Mr Commissioner. You can shrug, but it will be interesting to hear your perspective on this."@en1
lpv:spokenAs
lpv:unclassifiedMetadata
lpv:videoURI

Named graphs describing this resource:

1http://purl.org/linkedpolitics/rdf/English.ttl.gz
2http://purl.org/linkedpolitics/rdf/Events_and_structure.ttl.gz
3http://purl.org/linkedpolitics/rdf/spokenAs.ttl.gz

The resource appears as object in 2 triples

Context graph